CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Jupiter Neurosciences Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Jupiter Neurosciences Inc
1001 N US Highway 1, Suite 504
Phone: (302) 658-7581p:302 658-7581 PALM BEACH GARDENS, FL  33477  United States Fax: (302) 655-5049f:302 655-5049

Business Summary
Jupiter Neurosciences, Inc., formerly Jupiter Orphan Therapeutics, Inc., is a clinical stage research and development pharmaceutical company. The Company develops a resveratrol platform product targeting treatment of neuro-inflammation. The Company's product candidate, JOTROL, which primarily targets mucopolysaccharidoses Type 1, Friedreich’s Ataxia, and MELAS as well as amyotrophic lateral sclerosis (ALS) which is in an early development stage. The JOTROL delivery platform allows resveratrol to be consumed in a soft gel capsule form. It offers therapeutic benefit to central nervous system diseases such as Alzheimer’s disease, ataxias, and metabolic disorders such as Lysosomal Storage Disorders and mitochondrial diseases. It targets Mild Cognitive Impairment/early Alzheimer’s disease with traumatic brain injury (TBI)/concussions and Covid-19 in early development stages. The Company's product candidate, JOTROL, is in Phase I clinical trial.

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
9/30/202112/31/2020YesYes---

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Chairman of the Board, Chief Executive Officer, Co-Founder ChristerRosen 71 1/1/2016 1/1/2016
President, Chief Business Officer, Director Alison D.Silva 9/1/2021 1/1/2018
Co-Founder, Chief Administrative Officer AlexanderRosen 32 1/1/2016 1/1/2016
6 additional Officers and Directors records available in full report.

General Information
Number of Employees: 5 (As of 1/5/2022)
Outstanding Shares: 16,409,935 (As of 1/5/2022)
Stock Exchange: NASD
Federal Tax Id: 474828381
Fax Number: (302) 655-5049


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Tuesday, July 16, 2024